ARC1779

Phase 2Small molecule

AArchemix Corp.

ARC1779 is one of 32 small molecule programs targeting Von Willebrand disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Von Willebrand DiseaseActive, not recruiting

Thrombotic MicroangiopathyActive, not recruiting

Von Willebrand DiseasePhase 2

Active, not recruiting

Thrombotic MicroangiopathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

37 competitors in Von Willebrand Disease

#DrugCompanyPhaseTrials

Cyklokapron

AAmring

Phase 3

3 2

Advate

Takeda

Phase 3

2 3

Bypassing Agents

Biostate

3 5

Hemlibra

Roche

Phase 1

1 6

Recombinant Factor IX

BBaxalta now part of Shire

Phase 3

1 7

Rfviii

UUniversity of Pittsburgh

Phase 3

1 8

Wilate

Octapharma

Phase 3

1 9

Vonicog Alfa

Takeda

Phase 3

3 10

Factor VIII Concentrates

Roche

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Platelet Function1 trial

ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders

Completed·AArchemix Corp.·Phase 2·NCT00632242·28 enrolled

Tics1 trial

Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 in Healthy Volunteers

Completed·AArchemix Corp.·Phase 1·NCT00432770·42 enrolled

Thrombotic Microangiopathy1 trial

Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

Terminated·AArchemix Corp.·Phase 2·NCT00726544·100 enrolled

Carotid Endarterectomy1 trial

Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy

Terminated·AArchemix Corp.·Phase 2·NCT00742612·100 enrolled

Von Willebrand disease1 trial

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B

Withdrawn·AArchemix Corp.·Phase 2·NCT00694785·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for ARC1779. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARC1779 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARC1779. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Archemix Corp. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AArchemix Corp.

ARC1779

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Platelet Function1 trial

Tics1 trial

Thrombotic Microangiopathy1 trial

Carotid Endarterectomy1 trial

Von Willebrand disease1 trial

References

Drug Info

Quick Facts

Related News